Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) finished Wednesday with an addition of $0.02 to close at $1.09, an upside of 1.87 percent. An average of 3,141,580 shares of common stock have been traded in the last five days. There was a gain of $0.0800 in the past week. The last 20 days have seen an average of 2,081,110 shares traded, while the 50-day average volume stands at 2,652,808.
ADMP stock has increased by 2.83% in the last month. The company shares reached their 1-month lowest point of $0.9580 on 09/30/21. With the stock rallying to its 52-week high on 01/22/21, shares of the company touched a low of $0.38 and a high of $2.34 in 52 weeks. In spite of this, the price is down -53.42% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
328 days have passed since Adamis Pharmaceuticals Corporation (ADMP) last reported insider trading activity. Marguglio David J., who is SVP and Chief Business Officer, most recently acquired $35,000 shares at $0.40 per share on Nov 20. In this transaction, the insider spent $14,000. Chief Financial Officer, Hopkins Robert O, disposed of 35,000 shares at a price of $0.41 on Nov 20. The insider now owns more than $14,182 worth of shares. Prior to that, Chief Medical Officer Moss Ronald B. went on to Sale 8,532 shares at $0.41 each on Nov 18. An amount of $3,465 was transacted.
Adamis Pharmaceuticals Corporation (ADMP) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.30 for the sector. The stock’s beta is 1.29. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.84, the price-to-book (PB) ratio at 27.25.
The quick ratio of Adamis Pharmaceuticals Corporation for the three months ended December 30 was 0.50, and the current ratio was 0.60, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.26 and a total debt to equity ratio of 1.51 for the quarter ending December 30. On the profitability front, the trailing 12-month gross margin is 9.90% against a 5-year average of 28.6%. Adamis Pharmaceuticals Corporation’s EBITDA margin for the year ending December 30 is -154.59%. Its gross profit as reported stood at $1.63 million compared to revenue of $16.53 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Adamis Pharmaceuticals Corporation’s return on assets was -123.70%, compared to -77.8% over the last five years. In the past year, the return on investment has been -565.70%, and the 5-year average is -100.8%. Meanwhile, the return on equity (ROE) for the past 12 months has been -226.50% and the 5-year average holds at -125.9%. For the broader industry, ROE averaged -15.50 over the past year.
The analyst consensus anticipated Adamis Pharmaceuticals Corporation’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$0.24, a -300.00% surprise. For the quarter, EBITDA amounted to -$13.98 million. Shareholders own equity worth $148.89 million.
From a technical analysis perspective, let’s take a brief look at Adamis Pharmaceuticals Corporation (ADMP) price momentum. RSI 9-day as of the close on 13 October was 65.49%, suggesting the stock is Neutral, with historical volatility in this time frame at 29.33%.
As of today, ADMP’s price is $1.0560 +7.92% or $0.0800 from its 5-day moving average. ADMP is currently trading +0.93% higher than its 20-day SMA and +35.72% higher than its 100-day SMA. However, the stock’s current price level is +2.83% above the SMA50 and +111.49% above the SMA200.
The stochastic %K and %D were 70.23% and 68.14%, respectively, and the average true range (ATR) was 0.0609. With the 14-day stochastic at 68.75% and the average true range at 0.0607, the RSI (14) stands at 58.51%. The stock has reached 0.0344 on the 9-day MACD Oscillator while the 14-day reading was at 0.0490.
Maxim Group upgraded Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a a Hold.The consensus rating for Adamis Pharmaceuticals Corporation (ADMP) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ADMP, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is ADMP’s price target for the next 12 months?
Analysts predict a range of price targets between $1.50 and $1.50, with a median target of $1.50. Taking a look at these predictions, the average price target given by analysts for Adamis Pharmaceuticals Corporation (ADMP) stock is $1.50.